CERS vs MLAB
CERS: Cerus is a developer of blood safety technologies, specifically pathogen reduction systems designed to protect the blood supply from transfusion-transmitted infections. MLAB: Mesa Labs provides essential quality control instruments, consumables, and calibration services to protect patient safety and ensure product integrity in the life sciences and healthcare sectors.
Side-by-side fundamentals
| Metric | CERS | MLAB | Edge |
|---|---|---|---|
| Price as of 2026-08-10 close | $2.52 | $101.62 | |
| Market cap as of 2026-08-11 | $508M | $561M | |
| P/E as of 2026-08-11 | n/a | 84.45 | |
| Net margin as of 2026-08-11 | -2.7% | +2.7% | MLAB higher |
| Gross margin as of 2026-08-11 | +57.2% | +63.5% | MLAB higher |
| Operating margin as of 2026-08-11 | -0.7% | +7.4% | MLAB higher |
| ROE as of 2026-08-11 | -10.3% | +3.7% | MLAB higher |
| ROA as of 2026-08-11 | -3.1% | +1.6% | MLAB higher |
| Debt / equity as of 2026-08-11 | 0.93 | 0.81 | MLAB lower |
| Revenue growth (YoY) as of 2026-08-11 | +14.6% | +3.4% | CERS higher |
| Revenue CAGR (3y) SEC XBRL | +7.5% | +4.4% | CERS higher |
| Dividend yield as of 2026-08-11 | n/a | +0.6% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-11 | 1.80 | 1.02 | |
| 1-year return as of 2026-08-10 close | +108.3% | +58.1% | CERS higher |
Fundamentals: market data, as of 2026-08-11. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.